Literature DB >> 17166540

HIV-1 clones resistant to a small molecule CCR5 inhibitor use the inhibitor-bound form of CCR5 for entry.

Pavel Pugach1, Andre J Marozsan, Thomas J Ketas, Elissa L Landes, John P Moore, Shawn E Kuhmann.   

Abstract

Human immunodeficiency virus type 1 (HIV-1) infection can be inhibited by small molecules that target the CCR5 coreceptor. Here, we describe some properties of clonal viruses resistant to one such inhibitor, SCH-D, using both chimeric, infectious molecular clones and Env-pseudotypes. Studies using combinations of CCR5 ligands, including small molecule inhibitors, monoclonal antibodies (MAbs) and chemokine derivatives such as PSC-RANTES, show that the fully SCH-D-resistant viruses enter target cells by using the SCH-D-bound form of CCR5. However, the way resistance to SCH-D and other small molecule CCR5 inhibitors is manifested depends on the target cell and the nature of the assay (single- vs. multi-cycle). In multi-cycle assays using primary lymphocytes, SCH-D does not inhibit resistant molecular clones, and it can even enhance their infectivity modestly. In contrast, the same viruses (as Env-pseudotypes) are significantly inhibited by SCH-D in single-cycle entry assays using U87-CD4/CCR5 cells, resistance being manifested by incomplete inhibition at high SCH-D concentrations. When a single-cycle, Env-pseudotype entry assay was performed using either U87-CD4/CCR5 cells or PBMC under comparable conditions, entry was inhibited by up to 88% in the former cells but by only 28% in the PBMC. Hence, there are both cell- and assay-dependent influences on how resistance is manifested. We also take this opportunity to correct our previous report that SCH-D-resistant isolates are also substantially cross-resistant to PSC-RANTES [Marozsan, A.J., Kuhmann, S.E., Morgan, T., Herrera, C., Rivera-Troche, E., Xu, S., Baroudy, B.M., Strizki, J., Moore, J.P., 2005. Generation and properties of a human immunodeficiency virus type 1 isolate resistant to the small molecule CCR5 inhibitor, SCH-417690 (SCH-D). Virology 338 (1), 182-199]. A substantial element of this resistance was attributable to the unappreciated carry-over of SCH-D from the selection cultures into analytical assays.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17166540      PMCID: PMC1892195          DOI: 10.1016/j.virol.2006.11.004

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  38 in total

1.  Epitope mapping of CCR5 reveals multiple conformational states and distinct but overlapping structures involved in chemokine and coreceptor function.

Authors:  B Lee; M Sharron; C Blanpain; B J Doranz; J Vakili; P Setoh; E Berg; G Liu; H R Guy; S R Durell; M Parmentier; C N Chang; K Price; M Tsang; R W Doms
Journal:  J Biol Chem       Date:  1999-04-02       Impact factor: 5.157

Review 2.  Assessing chemokine co-receptor usage in HIV.

Authors:  Eoin Coakley; Christos J Petropoulos; Jeannette M Whitcomb
Journal:  Curr Opin Infect Dis       Date:  2005-02       Impact factor: 4.915

3.  Coreceptor usage of primary human immunodeficiency virus type 1 isolates varies according to biological phenotype.

Authors:  A Björndal; H Deng; M Jansson; J R Fiore; C Colognesi; A Karlsson; J Albert; G Scarlatti; D R Littman; E M Fenyö
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

4.  HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5.

Authors:  T Dragic; V Litwin; G P Allaway; S R Martin; Y Huang; K A Nagashima; C Cayanan; P J Maddon; R A Koup; J P Moore; W A Paxton
Journal:  Nature       Date:  1996-06-20       Impact factor: 49.962

Review 5.  The beta-chemokines, HIV type 1 second receptors, and exposed uninfected persons.

Authors:  W A Paxton; T Dragic; R A Koup; J P Moore
Journal:  AIDS Res Hum Retroviruses       Date:  1996-09-01       Impact factor: 2.205

6.  Differential inhibition of human immunodeficiency virus type 1 fusion, gp120 binding, and CC-chemokine activity by monoclonal antibodies to CCR5.

Authors:  W C Olson; G E Rabut; K A Nagashima; D N Tran; D J Anselma; S P Monard; J P Segal; D A Thompson; F Kajumo; Y Guo; J P Moore; P J Maddon; T Dragic
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

7.  Potent antiviral synergy between monoclonal antibody and small-molecule CCR5 inhibitors of human immunodeficiency virus type 1.

Authors:  Jose D Murga; Michael Franti; Daniel C Pevear; Paul J Maddon; William C Olson
Journal:  Antimicrob Agents Chemother       Date:  2006-10       Impact factor: 5.191

8.  Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1.

Authors:  E J Platt; K Wehrly; S E Kuhmann; B Chesebro; D Kabat
Journal:  J Virol       Date:  1998-04       Impact factor: 5.103

9.  Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG.

Authors:  A Trkola; A B Pomales; H Yuan; B Korber; P J Maddon; G P Allaway; H Katinger; C F Barbas; D R Burton; D D Ho
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

10.  Medicinal chemistry applied to a synthetic protein: development of highly potent HIV entry inhibitors.

Authors:  Oliver Hartley; Hubert Gaertner; Jill Wilken; Darren Thompson; Richard Fish; Alejandra Ramos; Cristina Pastore; Brigitte Dufour; Fabrice Cerini; Astrid Melotti; Nikolaus Heveker; Laurent Picard; Marc Alizon; Donald Mosier; Stephen Kent; Robin Offord
Journal:  Proc Natl Acad Sci U S A       Date:  2004-11-15       Impact factor: 11.205

View more
  87 in total

Review 1.  Drug resistance in HIV-1.

Authors:  Daniel R Kuritzkes
Journal:  Curr Opin Virol       Date:  2011-12       Impact factor: 7.090

2.  Sensitivity changes over the course of infection increases the likelihood of resistance against fusion but not CCR5 receptor blockers.

Authors:  Nikolaos Chatziandreou; Ana Belen Arauz; Ines Freitas; Phyu Hninn Nyein; Gregory Fenton; Shruti H Mehta; Gregory D Kirk; Manish Sagar
Journal:  AIDS Res Hum Retroviruses       Date:  2012-06-25       Impact factor: 2.205

Review 3.  The use of cell-delivered gene therapy for the treatment of HIV/AIDS.

Authors:  Geoff P Symonds; Helen A Johnstone; Michelle L Millington; Maureen P Boyd; Bryan P Burke; Louis R Breton
Journal:  Immunol Res       Date:  2010-12       Impact factor: 2.829

4.  HIV-1 resistance to CCR5 antagonists associated with highly efficient use of CCR5 and altered tropism on primary CD4+ T cells.

Authors:  Jennifer M Pfaff; Craig B Wilen; Jessamina E Harrison; James F Demarest; Benhur Lee; Robert W Doms; John C Tilton
Journal:  J Virol       Date:  2010-04-21       Impact factor: 5.103

Review 5.  Coreceptors and HIV-1 pathogenesis.

Authors:  Paul R Gorry; Petronela Ancuta
Journal:  Curr HIV/AIDS Rep       Date:  2011-03       Impact factor: 5.071

6.  Loss of asparagine-linked glycosylation sites in variable region 5 of human immunodeficiency virus type 1 envelope is associated with resistance to CD4 antibody ibalizumab.

Authors:  Jonathan Toma; Steven P Weinheimer; Eric Stawiski; Jeannette M Whitcomb; Stanley T Lewis; Christos J Petropoulos; Wei Huang
Journal:  J Virol       Date:  2011-02-02       Impact factor: 5.103

7.  Virologic failure in therapy-naive subjects on aplaviroc plus lopinavir-ritonavir: detection of aplaviroc resistance requires clonal analysis of envelope.

Authors:  Kathryn M Kitrinos; Heather Amrine-Madsen; David M Irlbeck; J Michael Word; James F Demarest
Journal:  Antimicrob Agents Chemother       Date:  2008-12-15       Impact factor: 5.191

8.  Reduction of CCR5 with low-dose rapamycin enhances the antiviral activity of vicriviroc against both sensitive and drug-resistant HIV-1.

Authors:  Alonso Heredia; Olga Latinovic; Robert C Gallo; Gregory Melikyan; Marv Reitz; Nhut Le; Robert R Redfield
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-15       Impact factor: 11.205

9.  Structure-function analysis of human immunodeficiency virus type 1 gp120 amino acid mutations associated with resistance to the CCR5 coreceptor antagonist vicriviroc.

Authors:  Robert A Ogert; Lei Ba; Yan Hou; Catherine Buontempo; Ping Qiu; Jose Duca; Nicholas Murgolo; Peter Buontempo; Robert Ralston; John A Howe
Journal:  J Virol       Date:  2009-09-23       Impact factor: 5.103

10.  HIV type 1 from a patient with baseline resistance to CCR5 antagonists uses drug-bound receptor for entry.

Authors:  John C Tilton; Heather Amrine-Madsen; John L Miamidian; Kathryn M Kitrinos; Jennifer Pfaff; James F Demarest; Neelanjana Ray; Jerry L Jeffrey; Celia C Labranche; Robert W Doms
Journal:  AIDS Res Hum Retroviruses       Date:  2010-01       Impact factor: 2.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.